HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy

Genome‐wide association studies (GWAS) recently indicated that polymorphisms in the human leucocyte antigen (HLA)‐DP genes were associated with risk of persistent hepatitis B virus (HBV) infection and clearance of HBV, but the effect of HLA‐DP gene polymorphisms on the effect of antiviral therapy was unknown. We here investigated whether such polymorphisms were associated with decreases in HBsAg levels and seroclearance in patients who received long‐term lamivudine (LAM) treatment.

[1]  M. Yuen,et al.  Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy , 2013, Hepatology.

[2]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[3]  Yoshiyuki Suzuki,et al.  Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study , 2013, Journal of Gastroenterology.

[4]  A. Koike,et al.  Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean , 2012, PloS one.

[5]  Hongbing Shen,et al.  Genetic variants in human leukocyte antigen/DP‐DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development , 2012, Hepatology.

[6]  A. Berger,et al.  A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers , 2012, PloS one.

[7]  Y. Kamatani,et al.  A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. , 2011, Human molecular genetics.

[8]  Ding‐Shinn Chen,et al.  Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy , 2011, Antiviral therapy.

[9]  E. Schadt,et al.  Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver , 2011, Genes and Immunity.

[10]  W. Tan,et al.  Strong influence of human leukocyte antigen (HLA)‐DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population , 2011, Hepatology.

[11]  D. Harnois,et al.  Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .

[12]  M. Manns,et al.  Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients , 2010, Hepatology.

[13]  M. Buti,et al.  Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients , 2009, The American Journal of Gastroenterology.

[14]  Y. Kamatani,et al.  A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians , 2009, Nature Genetics.

[15]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[16]  K. Simon,et al.  Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.

[17]  H. Tillmann,et al.  Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.

[18]  G. Liss,et al.  Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B , 2008 .

[19]  G. Makar.  Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD Al463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .

[20]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[21]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[22]  R. D. de Man,et al.  Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.

[23]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[24]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[25]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[26]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[27]  S. Nair,et al.  Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.

[28]  N. Leung,et al.  Chronic hepatitis B virus infection in Asian countries , 2000, Journal of gastroenterology and hepatology.

[29]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[30]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .